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Data surrounding sex‑specific differences in ANCA‑associated vasculitis glomerulonephritis 
(ANCA‑GN) outcomes is sparse. We hypothesised that the previously observed increased risk of 
end‑stage kidney disease (ESKD) in males is driven by sex‑specific variation in immunosuppression 
dosing. Patients were recruited to the Irish Rare Kidney Disease Registry or followed by the Royal Free 
Hospital vasculitis team (2012–2020). Inclusion criteria: prior diagnosis of ANCA‑GN (biopsy proven 
pauci‑immune glomerulonephritis) and positive serology for anti‑MPO or ‑PR3 antibodies. Renal and 
patient survival, stratified by sex and Berden histological class, was analysed. The cumulative‑ and 
starting dose/kilogram of induction agents and prednisolone, respectively, was compared between 
sexes. 332 patients were included. Median follow‑up was time 40.2 months (IQR 17.3–69.2). 73 (22%) 
reached ESKD and 47 (14.2%) died. Overall 1‑ and 5‑year renal survival was 82.2% and 76.7% in males 
and 87.1% and 82.0% in females, respectively (p 0.13). The hazard ratio for ESKD in males versus 
females, after adjustment for age, ANCA serology, baseline creatinine and histological class was 1.07 
(95% CI 0.59–1.93). There was no difference between sexes in the dose/kilogram of any induction 
agent. We did not observe a strong impact of sex on renal outcome in ANCA‑GN. Treatment intensity 
does not vary by sex.
ANCA-associated vasculitis (AAV) is a rare multi-system autoimmune disease, which results in rapidly progres-
sive glomerulonephritis and immune-mediated destruction of other organs. It is characterised by a necrotis-
ing pauci-immune small-vessel vasculitis, with a relapsing and remitting course. AAV comprises three main 
clinico-pathological syndromes: Microscopic polyangiitis (MPA), Granulomatosis with polyangiitis (GPA) and 
Eosinophilic granulomatosis with polyangiitis (EGPA). Despite treatment advances, AAV still carries a 2.7-fold 
increased risk of death compared with the general  population1 and a significant proportion of patients develop 
end-stage kidney disease (ESKD)2–4. The Berden histological classification system splits patients into four groups 
according to the predominant histological pattern: focal (≥ 50% normal glomeruli), crescentic (≥ 50% cellular 
crescents), sclerotic (≥ 50% globally sclerotic glomeruli) and mixed (all others). Multiple studies demonstrate 
that this classification system is predictive of ESKD  risk5–10.
Unlike most autoimmune diseases, AAV displays a slight male  predominance11,12, with the male: female 
ratio reported as 1.0:0.913. Proteinase 3 (PR3)-ANCA is more prevalent than myeloperoxidase (MPO)-ANCA 
in  males14. However, few data exist about sex-specific differences in AAV glomerulonephritis (ANCA-GN) 
outcomes. A recent  study14 demonstrated that males have a significantly higher risk of progression to ESKD, 
particularly in those with crescentic Berden class. A limitation of this study was the lack of personalised treat-
ment data to allow modelling for association with renal outcomes.
We sought to validate the findings of Bjørneklett et al.14 using a multi-national cohort, specifically, that the 
risk of developing ESKD is lower in females, across all histological classes of AAV. We also hypothesised that this 
difference would be based on a higher effective immunosuppression dose in women, due to lower lean body mass.
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Methods
Study participants. Participants of this retrospective cohort study were either previously recruited to the 
national Irish Rare Kidney Disease (RKD) Registry and  Biobank15, or followed by the vasculitis team at the 
Royal Free Hospital (RFH), London (United Kingdom (U.K.)), between 2012 and 2020. Participants had to 
have a prior diagnosis of AAV pauci-immune glomerulonephritis, confirmed on kidney biopsy, with at least 
three  glomeruli5,14, and positive serology for anti-MPO or -PR3 antibodies. Patients with secondary vasculitis or 
dual anti-glomerular basement membrane disease were excluded, in accordance with the European Medicines 
Agency  algorithm16. Ethical approval for the study was granted by the Tallaght University Hospital/St. James’s 
Hospital Joint Research Ethics Committee (ref 2018-10 List 33 (7)). All RKD participants provided written 
informed consent. In the U.K., the Health Research Authority decision tool determined that additional ethical 
approval was not required for the RFH cohort, as the study was deemed service evaluation. Our research was 
performed in accordance with relevant guidelines and regulations.
Study assessments. We collected data on age, sex, ethnicity, AAV phenotype, ANCA serotype, creatinine 
(µmol/L), weight (kg) and Berden score on renal biopsy. Treatment data was also collected, including cumulative 
induction cyclophosphamide and rituximab dose induction and the starting dose of prednisolone. To minimise 
the risk of incomplete induction treatment data, only cases with a realistic treatment schedule were included: > 3 
doses of IV cyclophosphamide or > 1 rituximab dose in the first 6 months of treatment. The observation period 
was from the date of diagnosis to the occurrence of the first event (ESKD, death or 30th September 2020).
Statistical analysis. The primary outcome was time to ESKD. ESKD was defined by commencement of 
renal replacement therapy (and continued for at least 90  days), including dialysis and renal transplantation. 
The secondary outcome was time to death. A composite of time to ESKD or death was also investigated. The 
cumulative dose per kilogram of each induction agent was calculated for a subgroup of participants for whom 
complete induction treatment data was available (n = 189). The starting dose of prednisolone per kilogram was 
also obtained. Continuous variables are reported as mean (standard deviation, SD) or median (interquartile 
range, IQR, if not normally distributed), and compared using the independent sample t-test or Mann–Whit-
ney U test, respectively. Categorical variables are summarised by frequency and percentage (%) and compared 
using the chi-square test. Renal survival was determined using Kaplan–Meier survival analysis. Analyses were 
censored for death or final visit. Between group comparisons were performed using the log-rank test. Renal and 
patient survival was stratified by sex and Berden histological class. Cox regression analysis was used to calculate 
the hazard ratio (HR) of ESKD in males versus females, with adjustment for age, ANCA serology, creatinine at 
diagnosis and Berden histological class. P < 0.05 was considered statistically significant. All statistical analyses 
were performed using RStudio (Version 1.2.5001). The following R packages were used: dplyr, forcats, tableone, 
ggplot2, survival and survminer.
Results
Participant characteristics. 332 patients met the inclusion criteria (Table 1), comprising 256 (77.1%) and 
76 (22.9%) patients from the Irish and British cohorts, respectively. The mean age was 62 years (SD 15) and 194 
(58.4%) were male, mainly Caucasian (92.2%). 217 (65.4%) were diagnosed with MPA, 92 (27.7%) GPA, 7 (2.1%) 
EGPA and 16 (4.8%) were unclassified AAV. 199 (60.1%) displayed MPO-ANCA positivity. Baseline creatinine 
was 278 µmol/L (IQR 158–450). Median follow-up time was 40.2 months (IQR 17.3–69.2). During this time, 73 
(22%) reached ESKD and 47 (14.2%) died.
Table 1 displays baseline characteristics stratified by sex. Females were older (mean age 65 years in females 
versus 61 years in males, p 0.009) with a trend towards more MPO-ANCA positivity compared to males (66.7% 
versus 55.4%, p 0.052). Males had slightly better renal function at baseline (eGFR 19 (10–38) mL/min/1.73  m2 
in males versus 16 (9–34) mL/min/1.73  m2 in females), but this was not statistically significant. Females were 
lighter (female mean weight 69.3 kg versus 82.5 kg in males, p < 0.001). There were no other significant differ-
ences in baseline characteristics between males and females.
Renal survival. Overall, renal survival was 84% (95% confidence interval (CI) 80–88) at 1 year and 79% 
(95% CI 74–84) at 5 years. We observed an excess of ESKD in males in the first six months after diagnosis, but 
the probability of ESKD was not significantly higher in males over the full period of observation (Fig. 1a). There 
was also no significant difference in renal survival between males and females when stratified by Berden histo-
logical class (Table 2 and Fig. 1b–e). The overall 1- and 5-year renal survival was 82.2% (95% CI 76.9–87.8) and 
76.7% (95% CI 70.4–83.5) in males and 87.1% (95% CI 81.6–93.1) and 82.0% (95% CI 75.0–89.7) in females, 
respectively. The hazard ratio (HR) for ESKD in males versus females, after adjustment for age, ANCA serology, 
baseline creatinine and histological class was 1.07 (95% CI 0.59–1.93, p 0.82).
Patient and renal survival. There was no difference in the composite outcome of patient and renal sur-
vival between sexes (Fig. 2), or when stratified by histological class (Table 3). Cox regression analysis showed that 
the HR for ESKD/death in males versus females, after adjustment for age, ANCA serology, baseline creatinine 
and histological class was 1.14 (95% CI 0.70–1.88, p 0.60).
Induction treatment stratified by sex. To test whether any observed effects of sex on survival may be 
influenced by standardised (non-weight based) dosing of immunosuppression, we analysed the weight adjusted 
doses delivered in those in whom complete data on individual induction immunosuppression was available 
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:13080  | https://doi.org/10.1038/s41598-021-92629-7
www.nature.com/scientificreports/
(n = 189). The median cumulative dose per kilogram for intravenous cyclophosphamide, oral cyclophosphamide 
and rituximab is shown Table 4. There was no significant difference between males and females for any agent.
Discussion
In our international, multi-centre study, we did not find a significant sex-specific difference in ANCA-GN out-
comes. This contrasts with the increased risk of progression to ESKD for Norwegian males with ANCA-GN, 
reported by Bjørneklett et al.14. Our findings were similar when combining ESKD and death as a composite 
outcome: there was no difference between males and females.
Norwegian males with ANCA-GN, reported by Bjørneklett et al.14, were found to have a 2.44-fold increased 
risk of ESKD (HR 2.44, 95% CI 1.56–3.82, p < 0.001), after adjustment for age, ANCA serology, eGFR, and 
histological classification. This is consistent with prior observations in all-cause CKD where kidney function 
declines more rapidly and the risk of ESKD is higher in  men17,18. Data from the Norwegian study was collected 
between 1991 and 2012 when the standard of care was oral cyclophosphamide. This differs from our study which 
commenced in 2012, after the publication of the CYCLOPS  trial19, after which intravenous cyclophosphamide 
gained popularity. It has been postulated that women are more adherent to daily oral medication regimes, which 
may play a role in the difference observed by Bjørneklett et al.14, but not in the later pulsed intravenous regimes 
which predominate in our study. Importantly, like the previous  study14, baseline kidney function in males was 
slightly better than in females, so this factor should not bias in favour of a better renal outcome in females, and 
baseline kidney function was included as a confounder in the multivariate model. Overall, our cohort had more 
advanced kidney disease at presentation: median baseline estimated Glomerular Filtration Rate (CKD-EPI, 
eGFR) 17.5 mL/min/1.73  m2, versus 34 mL/min/1.73  m2 in the Norwegian study. Despite this, and the higher 
proportion of MPO-ANCA positivity in our cohort (which in itself a risk factor for  ESKD20), a similar propor-
tion of patients in both cohorts progressed to ESKD, in keeping with that observed in other recent  work3. This 
observation probably reflects the improvement in overall AAV care over the last few  decades3, which may have 
eliminated the sex-specific discrepancy in renal outcome seen prior to 2012.
Table 1.  Baseline characteristics in the total cohort and stratified by sex. Missing data: baseline creatinine 
for females (n = 20), males (n = 27), weight for females (n = 20), males (n = 23). Rare Kidney Disease Registry 
(RKD), Ireland. Royal Free Hospital (RFH), London, U.K. Microscopic polyangiitis (MPA), Granulomatosis 
with polyangiitis (GPA), Eosinophilic granulomatosis with polyangiitis (EGPA), Estimated Glomerular 
Filtration Rate (CKD-EPI, eGFR) was calculated from baseline creatinine. *Frequency (%). **Mean (standard 
deviation). ***Median (inter-quartile range).
All Female Male p
N* 332 138 (41.6) 194 (58.4)
Origin = RKD /RFH* 256/76 (77.1/22.9) 99/39 (71.7/28.3) 157/37 (80.9/19.1) 0.067
Age at diagnosis** 62.5 (14.7) 65.0 (14.8) 60.7 (14.4) 0.009
Ethnicity* 0.729
White 306 (92.2) 125 (90.6) 181 (93.3)
Asian 12 (3.6) 6 (4.3) 6 ( 3.1)
Black 6 (1.8) 4 (2.9) 2 ( 1.0)
Mixed 3 (0.9) 1 (0.7) 2 ( 1.0)
Other 5 (1.5) 2 (1.4) 3 ( 1.5)
AAV phenotype* 0.18
MPA 217 (65.4) 96 (69.6) 121 (62.4)
GPA 92 (27.7) 31 (22.5) 61 (31.4)
EGPA 7 (2.1) 2 (1.4) 5 (2.6)
ANCA vasculitis unclassified 16 (4.8) 9 (6.5) 7 (3.6)
MPO-ANCA specificity* 199 (60.1) 92 (66.7) 107 (55.4) 0.052
Baseline creatinine (µmol/L)*** 278 [158.0, 450.0] 263 [140.5, 412.0] 288 [165.5, 504.5] 0.065
Baseline eGFR (mL/min/1.73  m2)*** 16 [9, 34] 19 [10, 38]
Weight (kg)** 77.1 (22.9) 69.3 (16.2) 82.5 (25.2)  < 0.001
Berden histological class* 0.415
Crescentic 97 (31.7) 42 (33.1) 55 (30.7)
Focal 90 (29.4) 37 (29.1) 53 (29.6)
Mixed 79 (25.8) 36 (28.3) 43 (24.0)
Sclerotic 40 (13.1) 12 ( 9.4) 28 (15.6)
Follow up (months)*** 40.2 [17.3, 69.2] 36.0 [15.5, 57.8] 41.5 [19.4, 75.7] 0.091
End-stage kidney disease* 73 (22.0) 24 (17.4) 49 (25.3) 0.116
Death* 47 (14.2) 21 (15.2) 26 (13.4) 0.758
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In contrast to the  literature14,21, we identified that MPO-ANCA is more prevalent than PR3-ANCA in males. 
We also identified a higher proportion of MPO-ANCA positivity overall (60.1%) compared to the Norwegian 
study (46.0%), which is in keeping with the known latitudinal gradient of PR3:MPO ANCA  specificity21. This 
highlights the heterogenous nature of AAV across different geographic regions, despite using identical inclusion 
criteria. This geographical diversity, potentially underpinned by  genetics22, may account for inconsistencies in 
renal outcome across different cohorts.
Figure 1.  Kaplan–Meier plots demonstrating renal survival in males versus females in (a) the entire cohort, and 
in those with (b) focal histology, (c) mixed histology, (d) crescentic histology and (e) sclerotic histology.
Table 2.  Renal survival at 1- and 5-years follow-up, stratified by gender and Berden classification. *Berden 
histological class missing in n = 26.
Characteristic
N ESKD 1-year 5-year
p valueMales Females Males Females













Focal 53 37 2 2 100 (1.0–1.0) 96.9 (91.0–1.0) 97.4 (92.4–1.0) 96.9 (91.0–1.0) 0.73
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Figure 2.  Kaplan–Meier plot demonstrating patient and renal survival in males versus females.
Table 3.  Patient and renal survival at 1- and 5-years follow-up, stratified by gender and Berden classification. 
*Berden histological class missing in n = 26.
Characteristic
N ESKD/death 1-year 5-year
p valueMales Females Males Females




























Sclerotic 28 12 19 8 40.8 (25.8–64.7) 64.8 (42.1–99.8)
35.7 (21.1–
60.6) 16.2 (3.1–85.0) 0.79
Missing* 15 11
Table 4.  Induction immunosuppression dose per kilogram, stratified by gender. Milligram (mg), kilogram 
(kg), intravenous (IV), oral (PO).
Drug (mg)
Median (IQR) (mg/kg)
N Female Male p value
Cumulative IV cyclophosphamide dose/kg 81 58.15 (53.38, 73.89) 64.23 (51.52, 79.48) 0.45
Cumulative PO cyclophosphamide dose/kg 49 86.70 (68.15, 146.92) 126.11 (74.07, 201.53) 0.35
Cumulative rituximab dose/kg 59 30.77 (23.53, 38.46) 28.85 (21.17, 32.60) 0.11
Starting prednisolone dose/kg 200 0.77 (0.64, 0.76) 0.71 (0.57, 0.70) 0.05
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We repeated the Kaplan–Meier analysis stratified for Berden histological class. In keeping with the original 
Berden description and the recent re-validation by van Daalen et al.10, we demonstrated that the focal subclass 
carries the best renal prognosis, while the sclerotic class performs the worst. The crescentic and mixed classes 
displayed similar prognosis. We did not observe an interaction between histological class and gender on ESKD 
risk. Notably, the large sex-specific difference observed by Bjørneklett et al.14 in patients with the crescentic 
subclass was not replicated in our cohort.
Our aim was to build on the findings of Bjørneklett et al.14 by using the very granular treatment data available 
to us, to explore whether their findings were due to sex-dependent variation in cumulative immunosuppression 
dosing, relative to body mass. We hypothesised that females received a higher effective induction immunosup-
pression dose due to their lower average body mass when fixed dosing regimens are administered. However, we 
found no difference between sexes in the cumulative dose normalised to body weight of any of the induction 
agents. It is possible we were underpowered to detect a difference as complete treatment data was missing in 
43% of the cohort, but our evidence suggests sex-dependent variation in treatment intensity is not a factor in 
determining renal outcome.
To our knowledge, our study is the second of its kind to investigate sex-specific differences in renal out-
comes in patients with AAV glomerulonephritis. Our large international multi-centre cohort study benefits 
from detailed longitudinal data including comprehensive individual treatment records. However, due to the 
observational nature of our data, there is a possibility that treatment data is incomplete, resulting in inaccurate 
conclusions. It also remains possible that our study is under-powered to detect small effects, although, if present, 
these would be unlikely to be clinically significant. To mitigate this we restricted this sub-analysis to include 
patients with a realistic cumulative dose (> 3 doses of IV cyclophosphamide or > 1 rituximab dose in the first 
6 months of treatment). Study endpoints were obtained retrospectively from hospital records. Therefore, there is 
a possibility that death records are incomplete if the event occurred outside of the hospital. However, given that 
AAV patients are generally followed up in hospital settings, this is unlikely. In addition, sustained chronic kidney 
disease stage 5 is increasingly recognised as part of the ESKD definition, but was not included in our study (in 
line with the Norwegian study). We chose to use identical inclusion criteria and definitions to Bjørneklett et al.14 
to enable accurate validation. Similarly, only biopsy proven cases were included, which results in selection bias 
towards more severe cases. It is possible that a significant difference in renal outcome exists between sexes when 
all patients with renal involvement are included.
In summary, we did not identify any clear sex-specific difference in renal outcome when stratified by Berden 
histological class. Furthermore, we found no evidence to support that any difference is due to sex-dependent 
variation in cumulative immunosuppression dosing. On the contrary, we found that weight-based dosing regi-
mens are now standard practice in Ireland, and treatment intensity does not vary by sex. There is a potential to 
further explore gender differences in well characterized registries with granular longitudinal follow-up, and to 
utilize the expanding interoperable nature of our European registries through initiatives such as  FAIRVASC23. 
When designing future multi-centre collaborative studies, we should consider the biopsychosocial influences of 
sex variance in AAV, in the context of outcomes and treatment- response and toxicity.
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